Trial Profile
A phase I/II feasibility study of the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor risk AML
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Panobinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON 116 AML
- Sponsors Janssen-Cilag; Novartis
- 16 Oct 2022 This trial has been completed in Netherlands (End Date: 2 Aug 2022) according to European Clinical Trials Database record.
- 06 Dec 2016 Interim results (n=54) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 23 Aug 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.